A Comparison of Pharmacologic Interventions in Pregnant Women with Opioid Use Disorder

Catherine M. Bopp
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters

Part of the Substance Abuse and Addiction Commons

Recommended Citation
https://commons.und.edu/pas-grad-posters/130

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please contact zeinebyousif@library.und.edu.
A Comparison of Pharmacologic Interventions in Pregnant Women with Opioid Use Disorder

Catherine M Bopp, PA-S
Department of Physician Assistant Studies, University of North Dakota School of Medicine & Health Sciences
Grand Forks, ND 58202-9037

Abstract
The purpose of this research and systematic literature review is to determine which pharmacologic agent - methadone or buprenorphine, leads to better outcomes in cases of pregnant mothers with opioid use disorder (OUD). Outcomes considered are maternal compliance, neonatal abstinence syndrome severity, and length of hospital stay. In the review, PubMed, Clinical Key, Cochrane Database of Systematic Reviews, and DynaMed Plus were searched. Key terms included were “methadone, buprenorphine, pregnancy,” “opioids, pregnancy,” “neonatal abstinence syndrome” and “medication assisted treatment, pregnancy.” Several studies were excluded, as their study population was not specified to have diagnosed OUD in pregnancy. The drawbacks to many of the studies is the inconsistencies in study conditions, and very small sample sizes. Much of the research presented shows evidence for the use of buprenorphine in the treatment of OUD in pregnancy. Buprenorphine seems to be a better medication assisted treatment (MAT) for the neonate in terms of reduced neonatal abstinence syndrome (NAS) and reduced length of hospital stay postpartum, while methadone still performs better for adherence for the mother. More research still needs to be done in order to demonstrate buprenorphine’s superior efficacy compared to methadone use in pregnant patients with OUD.

Keywords: MAT, methadone, buprenorphine, pregnancy, OUD, opioid, addiction, NAS, neonate

Introduction
Opioid addiction in the United States has become a major public health crisis. The Centers for Disease Control and Prevention (CDC) estimates that 134,000 die from opioid overdose each day. Neonates who are heavily exposed to opiates in utero often experience withdrawal upon parturition, a condition called neonatal abstinence syndrome (NAS). NAS increased by 25% in the US between 2000 and 2012. Treatment protocol supports the use of MAT to prevent NAS. Currently, methadone is administered to prevent pregnant women from abusing opiate substances, namely heroin or prescription opiate. However, a growing body of evidence supports other MAT drugs, most notably buprenorphine, for use in pregnant patients with NAS.

How OUD Medications Work in the Brain

New opioid medications are developed for the treatment of pain. Opioids are agonists at the mu-opioid receptors located in the brain. Methadone and buprenorphine are long-acting opioids, while opioid-like substances are short-acting opioids. Opioid-like drugs are often used to treat acute pain, while methadone and buprenorphine are used to treat chronic pain. Opioid-like drugs are often used to treat acute pain, while methadone and buprenorphine are used to treat chronic pain. Methadone is a full agonist at the mu-opioid receptors, while buprenorphine is a partial agonist at the mu-opioid receptors. Buprenorphine is more effective at reducing withdrawal symptoms in opioid-dependent individuals, while methadone is more effective at reducing craving.

Statement of the Problem
Methadone is the current standard of care for the use of MAT in pregnant women with OUD. Studies are needed to show the safety and efficacy of other treatment options such as buprenorphine for this patient population.

Research Questions
1. In pregnant patients with OUD, how effective is methadone compared to buprenorphine in the reduction of NAS?
2. In pregnant patients with OUD, how effective is methadone compared to buprenorphine in the reduction in length of hospital stay for neonates?
3. In pregnant patients with OUD, how effective is methadone compared to buprenorphine in retention on MAT and prevention of relapse?

Literature Review
Maintenance treatment provides a steady concentration of opiates in the pregnant woman’s blood and so prevents the adverse effects on the fetus of repeated withdrawals (Minozzi et al., 2013). In conjunction with psychosocial and cognitive behavioral therapy, MAT is endorsed over medically assisted withdrawal or abstinence for pregnant women with OUD by the Substance Abuse and Mental Health Services Administration and the American College of Obstetricians and Gynecologists Committee (Tran, Griffin, Stone, Vest, & Todd, 2017).

Fowler et al., (2013) found that buprenorphine led to better outcomes for neonates but had dropout rates of 56.4% compared to methadone. Also, buprenorphine led to a cost savings of over $12.4 million healthcare dollars.

Jansson et al., (2017) found that both methadone and buprenorphine, had a high dropout rate, and total length of hospitalization of neonates was 14.7 days on average.

A Cochrane review found that methadone treatment is less likely to drop out of the study (RR 0.64, 95% CI 0.41 to 1.01, n=223) compared to those on buprenorphine. There was no significant difference in the number of newborns treated for NAS, but evidence is considered very low (RR 1.22, 95% CI 0.89 to 1.67, three studies, n=166) (Minozzi et al., 2013).

The MOTHER study by Jones et al., (2010) showed discontinuation of treatment occurred in 18% of women in methadone treatment and 33% of women in buprenorphine treatment (p=0.02). The number of neonates requiring NAS treatment was not significantly different between groups (p=0.26). Neonates from the buprenorphine group needed 9% less methadone than those exposed to methadone (p=0.0091) and spent 43% less time in the hospital (p=0.0091).

Pregnant women addicted to intravenous heroin were studied in a five-year randomized prospective comparative study by Binder and Vávřinková (2008). The degree of NAS severity was 82.9 (Tran, Griffin, Stone, Vest, & Todd, 2017).

Discussion
Although buprenorphine is not the standard of care for pregnant women with OUD, it should be considered as an alternative to methadone maintenance therapy, though more women sustain MAT with methadone. Because NAS is less severe with buprenorphine compared to methadone, MAT length of stay (LOS) is less with buprenorphine exposed neonates and a more effective way to spend the very limited healthcare dollars that exist for these patients. In addition, MAT drug choice should be individual. Finally, if one MAT drug is failed, another should be initiated.

Literature Review
Methadone Versus Buprenorphine

Applicability to Clinical Practice
North Dakota experiences opioid addiction across the state but faces challenges for patients to get the care they need due to a lack of specialists and a vastness of rural geographic. Since stigma still exists with MAT, providers should be given the tools to screen, refer, and care for pregnant women with OUD. Withdrawal during pregnancy should be discouraged, and personal judgements withheld.

Project ECHO on “Extension for Community Healthcare Outcomes” is a hub and spoke model used to train rural providers with resources and information through video conferencing. Project ECHO is focused on the opioid epidemic in North Dakota and provides video sessions weekly from experts and specialists in academic or health care centers to primary care teams in rural parts of the state.

Champion Prescriber initiative expands access to MAT in North Dakota. These providers provide MAT treatment and overdose prevention education, collaborate with providers in project ECHO, and provide training on the use of Naloxone.

The First Steps to Healthy Babies service provided by Sanford in Bemidji, MN aims to help women have safe and healthy pregnancies and encourages sobriety with support services. They have seen a significant increase in the number of mothers who undergo MAT during pregnancy and are able to return home with their infant.

References

Acknowledgements
I want to give special thanks to the UND Department of PA Studies, especially Dr. Jeanie McGhoo and Professor Daryl Sieg. Dr. McGhoo was instrumental in advising and Professor Sieg offered expert guidance on this project. I also would like to thank Dr. Marilyn Klug for providing statistical insights and Dr. Messy Henke for offering valuable clinical insights. I would also like to thank Jenny Brown, PA-S for her review of my project. I would also like to thank my family, boyfriend, and classmates for their support.